HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors

International Journal of Cancer

Volumn 123, Issue 5, 2008, Pages 1146-1153

  Borgquist, Signe ^a,b   Djerbi, Soraya ^c   Pontén, Fredrik ^d   Anagnostaki, Lola ^a   Goldman, Malin ^a   Gaber, Alexander ^a   Manjer, Jonas ^b   Landberg, Göran ^a   Jirström, Karin ^a,e  

^a Malmö University Hospital   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c ALBANOVA UNIVERSITY CENTER   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Histopathology; HMG CoA reductase; Hormone replacement therapy; Obesity

Indexed keywords

ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; KI 67 ANTIGEN; PROTEIN P27; TUMOR MARKER;

ANTHROPOMETRIC PARAMETERS; ARTICLE; BREAST CANCER; CANCER STAGING; CELL HETEROGENEITY; CELL NUCLEUS; CYTOPLASM; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAJOR CLINICAL STUDY; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RISK FACTOR; STATISTICAL SIGNIFICANCE; TUMOR CELL; TUMOR VOLUME; WAIST CIRCUMFERENCE; ABDOMINAL FAT; BREAST TUMOR; ENZYMOLOGY; ESTROGEN THERAPY; GENE EXPRESSION REGULATION; MIDDLE AGED; PATHOLOGY; WAIST HIP RATIO;

ABDOMINAL FAT; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; IMMUNOHISTOCHEMISTRY; INCIDENCE; MIDDLE AGED; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; WAIST-HIP RATIO;

EID: 47249094123     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23597     Document Type: Article

References (29)

1. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood). 2004;229:567-85.
2. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
3. Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ, Chang M, Nolan GP, et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 2007;110:2674-84.
4. Di Croce L, Bruscalupi G, Trentalance A. Independent behavior of rat liver LDL receptor and HMGCoA reductase under estrogen treatment. Biochem Biophys Res Commun 1996;224:345-50.
5. Ma PT, Yamamoto T, Goldstein JL, Brown MS. Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17 alpha-ethinyl estradiol. Proc Natl Acad Sci USA 1986;83:792-6.
6. Di Croce L, Vicent GP, Pecci A, Bruscalupi G, Trentalance A, Beato M. The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogen-responsive region. Mol Endocrinol 1999;13:1225-36.
7. Messa C, Notarnicola M, Russo F, Cavallini A, Pallottini V, Trentalance A, Bifulco M, Laezza C, Gabriella Caruso M. Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells. Scand J Gastroenterol 2005;40:1454-61.
8. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997;32:403-25.
9. Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 2006;5:2310-6.
10. Campbell J, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, et al. Breast cancer growth prevention by statins. Cancer Res 2006;66:8707-14.
11. Duncan RE, Lau D, El-Sohemy A, Archer MC. Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity. Biochem Pharmacol 2004;68:1739-47.
12. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004;22:2388-94.
13. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771-7.
14. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92.
15. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007;16:416-21.
16. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005;23:8606-12.
17. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993;233:45-51.
18. Yasui T, Uemura H, Umino Y, Takikawa M, Saito S, Kuwahara A, Matsuzaki T, Maegawa M, Furumoto H, Miura M, Irahara M. Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women. Maturitas 2005;50:19-29.
19. [Histological typing of breast tumors. Second edn. World Health Organization. Geneva, 1981]. Ann Pathol 1982;2:91-105.
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
21. Borgquist S, Anagnostaki L, Jirstrom K, Landberg G, Manjer J. Breast tumours following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer 2007;120:2202-7.
22. Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, Watters AD, Cooke T, Paish C, Wencyk PM, Pinder SE. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-23.
23. Huang Z, Willett WC, Colditz GA, Hunter DJ, Manson JE, Rosner B, Speizer FE, Hankinson SE. Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study. Am J Epidemiol 1999;150:1316-24.
24. Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2004;13:220-4.
25. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, Stefanick ML, McTiernan A. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002;13:741-51.
26. Celis JE, Gromova I, Gromov P, Moreira JM, Cabezon T, Friis E, Rank F. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett 2006;580:2935-44.
27. Sever N, Yang T, Brown MS, Goldstein JL, DeBose-Boyd RA. Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. Mol Cell 2003;11:25-33.
28. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
29. Aboushadi N, Shackelford JE, Jessani N, Gentile A, Krisans SK. Characterization of peroxisomal 3-hydroxy-3-methylglutaryl coenzyme A reductase in UT2 cells: sterol biosynthesis, phosphorylation, degradation, and statin inhibition. Biochemistry 2000;39:237-47.